[go: up one dir, main page]

DK3115370T3 - Biologisk aktive peptider - Google Patents

Biologisk aktive peptider Download PDF

Info

Publication number
DK3115370T3
DK3115370T3 DK16172509.8T DK16172509T DK3115370T3 DK 3115370 T3 DK3115370 T3 DK 3115370T3 DK 16172509 T DK16172509 T DK 16172509T DK 3115370 T3 DK3115370 T3 DK 3115370T3
Authority
DK
Denmark
Prior art keywords
biologically active
active peptides
peptides
biologically
active
Prior art date
Application number
DK16172509.8T
Other languages
English (en)
Inventor
Friedrich Scheiflinger
Michael Dockal
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Application granted granted Critical
Publication of DK3115370T3 publication Critical patent/DK3115370T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK16172509.8T 2008-04-17 2009-04-16 Biologisk aktive peptider DK3115370T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US932608P 2008-04-17 2008-04-17
US11305508P 2008-11-10 2008-11-10
EP09743243.9A EP2279200B1 (en) 2008-04-17 2009-04-16 Biologically active peptides

Publications (1)

Publication Number Publication Date
DK3115370T3 true DK3115370T3 (da) 2019-07-29

Family

ID=40887122

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16172509.8T DK3115370T3 (da) 2008-04-17 2009-04-16 Biologisk aktive peptider
DK09743243.9T DK2279200T3 (da) 2008-04-17 2009-04-16 Biologisk aktive peptider

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09743243.9T DK2279200T3 (da) 2008-04-17 2009-04-16 Biologisk aktive peptider

Country Status (19)

Country Link
US (6) US8563688B2 (da)
EP (2) EP2279200B1 (da)
JP (3) JP6038452B2 (da)
KR (2) KR101434712B1 (da)
CN (2) CN102007140B (da)
AR (1) AR071478A1 (da)
AU (1) AU2009244635B2 (da)
BR (1) BRPI0911203A2 (da)
CA (1) CA2721694C (da)
DK (2) DK3115370T3 (da)
ES (2) ES2739676T3 (da)
HK (1) HK1223946A1 (da)
MX (1) MX2010011397A (da)
NZ (1) NZ588200A (da)
PL (1) PL2279200T3 (da)
PT (1) PT2279200T (da)
SG (2) SG10201809286XA (da)
TW (2) TWI541020B (da)
WO (1) WO2009137256A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541020B (zh) * 2008-04-17 2016-07-11 巴克斯歐塔公司 生物活性胜肽
JP2013502458A (ja) 2009-08-24 2013-01-24 アムニクス オペレーティング インコーポレイテッド 凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法
WO2012012444A2 (en) 2010-07-19 2012-01-26 Dolby Laboratories Licensing Corporation Enhancement methods for sampled and multiplexed image and video data
PL2717898T3 (pl) 2011-06-10 2019-06-28 Bioverativ Therapeutics Inc. Związki o działaniu prokoagulacyjnym i sposoby ich stosowania
PT3564260T (pt) 2012-02-15 2023-01-18 Bioverativ Therapeutics Inc Composições de fator viii e métodos de produção e utilização das mesmas
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CA2915389C (en) * 2013-06-11 2019-06-04 Cj Cheiljedang Corporation L-isoleucine-producing corynebacterium glutamicum strain and method of producing l-isoleucine therefrom
WO2015023894A1 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Recombinant factor viii proteins
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
US9321812B2 (en) 2014-03-28 2016-04-26 Perle Bioscience Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
JP6484468B2 (ja) * 2014-06-03 2019-03-13 ＡｖａｎＳｔｒａｔｅ株式会社 ガラス板製造方法およびガラス板製造装置
GB201410507D0 (en) * 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
AU2017336440B2 (en) 2016-09-28 2022-06-02 Cohbar, Inc. Therapeutic MOTS-c related peptides
JP7748175B2 (ja) 2016-12-02 2025-10-02 バイオベラティブ セラピューティクス インコーポレイテッド キメラ凝固因子を使用して血友病性関節症を処置する方法
BR112019015569A2 (pt) 2017-01-31 2020-03-17 Bioverativ Therapeutics Inc. Proteínas de fusão do fator ix e métodos para a sua produção e uso
CN112512555A (zh) 2018-05-18 2021-03-16 比奥维拉迪维治疗股份有限公司 治疗血友病a的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
JPH0725794B2 (ja) * 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
DK0693924T4 (da) 1993-02-22 2008-08-04 Abraxis Bioscience Inc Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
AU711935B2 (en) * 1994-12-30 1999-10-21 Seminis Vegetable Seeds, Inc. Papaya ringspot virus replicase gene
US5532153A (en) * 1995-03-23 1996-07-02 New England Biolabs, Inc. Method for cloning and producing the SacI restriction endonuclease
US7279548B2 (en) * 1996-04-03 2007-10-09 Cytogen Corporation Identification and isolation of novel polypeptides having WW domains and methods of using same
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US6624289B1 (en) 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
JP2003503426A (ja) 1999-07-02 2003-01-28 ジェネンテック・インコーポレーテッド ＦＶＩＩａアンタゴニスト
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
AU2065801A (en) * 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
US20020197266A1 (en) * 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
AU2002256518B2 (en) * 2001-05-11 2007-07-19 Research Development Foundation Inhibitors of receptor activator of NF-kappaB and uses thereof
FR2830865B1 (fr) * 2001-10-17 2004-10-22 Centre Nat Rech Scient Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes
US20060204503A1 (en) * 2005-01-31 2006-09-14 Biogen Idec Ma Inc. Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors
CA2632714A1 (en) * 2005-12-07 2007-06-14 Technische Universitaet Muenchen Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
JP2009526754A (ja) 2006-01-04 2009-07-23 ドゥ−コープ テクノロジーズ リミテッド 医薬剤のインビボ取り込みを強化するための組成物および方法
TWI541020B (zh) * 2008-04-17 2016-07-11 巴克斯歐塔公司 生物活性胜肽

Also Published As

Publication number Publication date
US20120077749A1 (en) 2012-03-29
NZ588200A (en) 2012-11-30
TW200944226A (en) 2009-11-01
US20190225648A1 (en) 2019-07-25
PL2279200T3 (pl) 2017-08-31
AU2009244635A1 (en) 2009-11-12
US8563688B2 (en) 2013-10-22
US10287319B2 (en) 2019-05-14
DK2279200T3 (da) 2016-08-22
US20150038676A1 (en) 2015-02-05
ES2594706T3 (es) 2016-12-22
JP2014074052A (ja) 2014-04-24
CA2721694C (en) 2018-11-06
US20160060295A1 (en) 2016-03-03
US9598464B2 (en) 2017-03-21
CN105524163A (zh) 2016-04-27
JP5977223B2 (ja) 2016-08-24
KR20130112959A (ko) 2013-10-14
EP2279200A1 (en) 2011-02-02
TW201443085A (zh) 2014-11-16
TWI541020B (zh) 2016-07-11
ES2739676T3 (es) 2020-02-03
CN102007140A (zh) 2011-04-06
SG10201809286XA (en) 2018-11-29
HK1223946A1 (zh) 2017-08-11
US20100022445A1 (en) 2010-01-28
JP2011518179A (ja) 2011-06-23
TWI573806B (zh) 2017-03-11
JP2017019797A (ja) 2017-01-26
MX2010011397A (es) 2010-11-12
KR101606248B1 (ko) 2016-03-24
KR101434712B1 (ko) 2014-10-01
CN102007140B (zh) 2016-02-24
AR071478A1 (es) 2010-06-23
BRPI0911203A2 (pt) 2016-07-05
US8822638B2 (en) 2014-09-02
US10822376B2 (en) 2020-11-03
HK1154255A1 (zh) 2012-04-13
CA2721694A1 (en) 2009-11-12
EP3115370A1 (en) 2017-01-11
SG10201608071YA (en) 2016-11-29
US9206234B2 (en) 2015-12-08
WO2009137256A1 (en) 2009-11-12
EP2279200B1 (en) 2016-07-13
KR20110005873A (ko) 2011-01-19
AU2009244635B2 (en) 2012-04-19
PT2279200T (pt) 2016-10-12
US20170174724A1 (en) 2017-06-22
EP3115370B1 (en) 2019-06-26
JP6038452B2 (ja) 2016-12-07

Similar Documents

Publication Publication Date Title
DK3115370T3 (da) Biologisk aktive peptider
BRPI0911743A2 (pt) "peptídeo"
EP2215246A4 (en) PROTEIN SCAFFOLDS
EP2346734A4 (en) ACTIVE WINGLET
PL2465864T3 (pl) Szczepionki z peptydem pochodzącym z Eph4
HRP20151120T1 (xx) Polipeptid ace2
BRPI0814587A2 (pt) Peptídeos antibióticos
DK2307543T3 (da) Forbedret proteinekspressionssystem
BRPI0812753A2 (pt) Combinações de substância ativas acaricidas
DK3118220T3 (da) Protein
EP2320221A4 (en) ELECTRODE
BRPI0812134A2 (pt) Anatagonistas de cxcr4 de peptídio cíclico
EP2251932A4 (en) ARTIFICIAL MEDIUM
BRPI0814971A2 (pt) Proteína
EP2437770A4 (en) ANTIMICROBIAL PEPTIDES
EP2352730A4 (en) BIOLOGICAL ACTIVE AMIDE
EP2010561A4 (en) ANTIMICROBIAL PEPTIDES
BRPI1010661A2 (pt) peptídeo
HRP20150195T1 (xx) Antibakterijski peptidi
BRPI0908722A2 (pt) reformadora ativa
DK2133416T3 (da) Rekombinant mikroorganisme
DK2207790T3 (da) Biologisk aktive C-terminalt argininholdige peptider
EP2557088A4 (en) PHYSIOLOGICALLY ACTIVE PEPTIDES
BRPI0916990A2 (pt) Combinações inseticidas
HRP20170146T1 (hr) Pufa-prekriveni implantati